These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6673058)

  • 1. Prednisolone pharmacokinetics and protein-binding in patients with portosystemic shunt.
    Bergrem H; Ritland S; Opedal I; Bergan A
    Scand J Gastroenterol; 1983 Mar; 18(2):273-6. PubMed ID: 6673058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum protein-binding.
    Bergrem H; Opedal I
    Scand J Gastroenterol; 1983 May; 18(4):545-9. PubMed ID: 6669930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding.
    Powell LW; Axelsen E
    Gut; 1972 Sep; 13(9):690-6. PubMed ID: 4639403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects.
    Uribe M; Go VL; Kluge D
    J Clin Gastroenterol; 1984 Aug; 6(4):331-5. PubMed ID: 6481116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of uremia on pharmacokinetics and protein binding of prednisolone.
    Bergrem H
    Acta Med Scand; 1983; 213(5):333-7. PubMed ID: 6880855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease.
    Uribe M; Summerskill WH; Go VL
    Clin Pharmacokinet; 1982; 7(5):452-9. PubMed ID: 7140120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prednisone and prednisolone bioavailability in renal transplant patients.
    Gambertoglio JG; Frey FJ; Holford NH; Birnbaum JL; Lizak PS; Vincenti F; Feduska NJ; Salvatierra O; Amend WJ
    Kidney Int; 1982 Apr; 21(4):621-6. PubMed ID: 7047863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased first-pass metabolism of labetalol in chronic liver disease.
    Homeida M; Jackson L; Roberts CJ
    Br Med J; 1978 Oct; 2(6144):1048-50. PubMed ID: 709214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.
    Schalm SW; Summerskill WH; Go VL
    Gastroenterology; 1977 May; 72(5 Pt 1):910-3. PubMed ID: 849821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
    Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The absence of effect of azathioprine on prednisolone pharmacokinetics following maintenance prednisone doses in kidney transplant patients.
    Gambertoglio JG; Holford HG; Lizak PS; Birnbaum JL; Salvatierra O; Amend WJ
    Am J Kidney Dis; 1984 May; 3(6):425-9. PubMed ID: 6372445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered prednisolone pharmacokinetics in patients treated with rifampicin.
    Bergrem H; Refvem OK
    Acta Med Scand; 1983; 213(5):339-43. PubMed ID: 6880856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid pharmacokinetics in liver disease.
    Uribe M; Go VL
    Clin Pharmacokinet; 1979; 4(3):233-40. PubMed ID: 383357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration.
    Bergrem H; Grøttum P; Rugstad HE
    Eur J Clin Pharmacol; 1983; 24(3):415-9. PubMed ID: 6861855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability assessment of a liquid prednisone preparation.
    Georgitis JW; Flesher KA; Szefler SJ
    J Allergy Clin Immunol; 1982 Oct; 70(4):243-7. PubMed ID: 7119300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of sucralfate on prednisone bioavailability.
    Gambertoglio JG; Romac DR; Yong CL; Birnbaum J; Lizak P; Amend WJ
    Am J Gastroenterol; 1987 Jan; 82(1):42-5. PubMed ID: 3799579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose dependent pharmacokinetics of prednisolone.
    Pickup ME; Lowe JR; Leatham PA; Rhind VM; Wright V; Downie WW
    Eur J Clin Pharmacol; 1977 Nov; 12(3):213-9. PubMed ID: 590308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum prednisolone levels in Crohn's disease and coeliac disease following oral prednisolone administration.
    Tanner AR; Halliday JW; Powell LW
    Digestion; 1981; 21(6):310-5. PubMed ID: 7250552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection.
    Frey BM; Seeberger M; Frey FJ
    Transplantation; 1985 Mar; 39(3):270-4. PubMed ID: 3883592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prednisolone disposition and protein binding in oral contraceptive users.
    Boekenoogen SJ; Szefler SJ; Jusko WJ
    J Clin Endocrinol Metab; 1983 Apr; 56(4):702-9. PubMed ID: 6833459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.